Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 5/20 | 0.33 |
| ▸ | MAP4K1 | Q92918 | 2/20 | 0.32 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.32 |
| ▸ | QPCT | Q16769 | 4/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3043808 | 0.91 | POLB (0.33) | HSD11B1QPCTOPRM1OPRK1 | |
| SCHEMBL3048636 | 0.91 | HSD11B1 (0.33) | HSD11B1QPCTOPRM1OPRK1 | |
| SCHEMBL3050325 | 0.88 | HSD11B1 (0.33) | HSD11B1SLC2A1QPCT | |
| SCHEMBL3047256 | 0.87 | HSD11B1 (0.32) | HSD11B1SLC2A1 | |
| SCHEMBL3044451 | 0.85 | VSIR (0.34) | OPRM1OPRK1 | |
| SCHEMBL1875561 | 0.82 | HSD11B1 (0.33) | HSD11B1QPCT | |
| Trifluoroacetic Acid SCHEMBL3050605 | 0.81 | SLC2A1 (0.48) | SLC2A1 | |
| SCHEMBL1874617 | 0.79 | QPCT (0.34) | HSD11B1QPCT | |
| SCHEMBL3040341 | 0.79 | HSD11B1 (0.34) | HSD11B1QPCT | |
| SCHEMBL3337459 | 0.78 | SLC2A1 (0.37) | SLC2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100222345-A1 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS | SMITHKLINE BEECHAM CORPORATION | 2010-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222345-A1 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS | OPRL1, OPRM1, OPRK1 | HSD11B1 1860/4885MAP4K1 1613/4885SLC2A1 4262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.